Menu Search
Equities

Rhythm Biosciences Ltd

0RY:FRA

Rhythm Biosciences Ltd

Actions
  • Price (EUR)0.0415
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-83.51%
  • Beta--
Data delayed at least 15 minutes, as of Jun 03 2024 08:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rhythm Biosciences Limited is an Australia-based medical diagnostics company. The Company is engaged in the development and commercialization of Australian medical diagnostics technology for sale in domestic and international markets. The Company’s ColoSTAT a blood-base cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or unwilling to use available screening modalities. ColoSTAT is indicated to screen adults, aged 40 to 85, at average risk for developing Colorectal Cancer (CRC). The test-kit measures five specific biomarkers in the blood that either increase or decrease in quantity when CRC tumors are present.

  • Revenue in AUD (TTM)157.67k
  • Net income in AUD-8.63m
  • Incorporated2017
  • Employees--
  • Location
    Rhythm Biosciences LtdBio21 Institute30 Flemington Road, ParkvilleMELBOURNE 3010AustraliaAUS
  • Phone+61 39614-0600
  • Fax+61 39614-0550
  • Websitehttps://www.rhythmbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.